APP and Alzheimer disease: ESR1 (estrogen receptor α), PTGS2 (cyclooxygenase-2), ALOX12 (12-lipoxygenase), AChE, GABRG1 (gamma-aminobutyric acid A receptor), TNF (tumor necrosis factor alpha), BACE1 (β-secreatase), APP (β-amyloid precursor protein), CDK5 (cyclin-dependent kinase 5), MAPT (microtubule-associated protein tau), GSK3β (glycogen synthase kinase 3 beta) and MAOB (monoamine oxidase B) were hub targets of the network, which suggested that they were main targets for XXMD formula to treat with AD.